Madrigal Pharmaceuticals, Inc. (LON: 0JXI)

London flag London · Delayed Price · Currency is GBP · Price in USD
303.56
+27.75 (10.06%)
At close: Jan 21, 2025
31.81%
Market Cap 5.75B
Revenue (ttm) 57.31M
Net Income (ttm) -386.98M
Shares Out n/a
EPS (ttm) -18.67
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 818
Average Volume 175
Open 293.23
Previous Close 275.80
Day's Range 285.43 - 305.26
52-Week Range 133.57 - 288.77
Beta -0.76
RSI 54.23
Earnings Date Feb 25, 2025

About Madrigal Pharmaceuticals

Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of non-alcoholic steatohepatitis (NASH) in the United States. Its lead product candidate is resmetirom, a liver-directed thyroid hormone receptor beta agonist, which is in Phase 3 clinical trials for treating NASH. The company is headquartered in West Conshohocken, Pennsylvania. [Read more]

Industry Pharmaceutical Preparations
CEO William Sibold
Employees 376
Stock Exchange London Stock Exchange
Ticker Symbol 0JXI
Full Company Profile

Financial Performance

Financial numbers in USD Financial Statements

News

There is no news available yet.